Doable predictive biomarkers for tumor reaction to mTOR inhibitors, as have been described in glioblastoma, breast and prostate cancer cells, will be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6.[1] Hence, this knowledge is predicated on preclinical assays, depending on in vitro cultured tumor cell traces, which https://hippoy853mrv6.win-blog.com/profile